French Agency for Veterinary Medicinal Products

↘ The French Agency for Veterinary Medicinal Products (ANMV) ensures that the veterinary medicines used in France are effective, safe for animal and human health, and environmentally friendly.

Part of the French Agency for Food, Environmental and Occupational Health & Safety (ANSES), the ANMV is also involved in work on animal diseases, antimicrobial resistance and chemical risks. It is based near Fougères in Ille-et-Vilaine and employs 80 people.

Each year

More than 6,000 administrative decisions relating to veterinary medicines and pharmaceutical establishments

—

Around 600 inspection days to ensure that veterinary pharmaceutical establishments comply with good practice

—

Nearly 5,000 reports of adverse effects assessed

—

Nearly 600 laboratory analyses conducted on over 100 medicinal products

—

Guaranteeing the safety and effectiveness of veterinary medicines

The ANMV assesses applications and issues marketing authorisations. Through its inspections, it guarantees high standards in the manufacture and distribution of veterinary medicinal products. It also issues authorisations to open pharmaceutical establishments. It monitors and studies potential health impacts on treated animals, the people administering or coming into contact with medicines, and the environment.

Veterinary medicinal products

- Assesses marketing authorisation (MA) applications;
- Issues MAs and import and export authorisations;
- Issues temporary use authorisations;
- Assesses maximum residue limits of veterinary medicinal products in foodstuffs of animal origin;
- Authorises clinical trials;
- Verifies the quality of veterinary medicinal products placed on the market;
- Monitors advertising;
- Monitors adverse effects observed in France and combats antimicrobial resistance.

Establishments

- Authorises the opening of establishments for manufacturing, licensed operation, wholesale distribution and export of veterinary medicinal products;
- Inspects veterinary pharmaceutical establishments.

Overseeing veterinary pharmacovigilance

Veterinarians and pet owners can **report online any adverse effects** of veterinary medicinal products occurring in animals or humans.
After analysing the report, the ANMV takes the most appropriate measures, which may include adding precautions for use to the package leaflet, withdrawing the product from the market, etc.
This monitoring also enables cases of misuse to be identified, such as human medicines given to pets without veterinary advice, or accidents due to confusion between medicines.

FIND OUT MORE

Combating resistance to veterinary antibiotics

By monitoring sales of veterinary antibiotics, the ANMV can verify the effectiveness of public policies designed to **reduce the use of antibiotics** in veterinary medicine. Its sales survey is gradually being supplemented by the monitoring of uses. These data, combined with the monitoring of bacterial resistance, are then used for assessing the risks associated with antimicrobial resistance in animal health.
The ANMV is also involved in European work aiming at **adapting the regulations** in order to more effectively combat antimicrobial resistance.

FIND OUT MORE

Playing a leading role in Europe and internationally

The ANMV is actively involved in producing and developing regulatory texts and guidelines, within the bodies regulating veterinary pharmaceuticals. It serves on 90 European and international working groups and is very active at European and international level, with the **European Medicines Agency** (EMA) and network of European Heads of Medicines Agencies (HMA), and in the area of international cooperation. Lastly, it is a **World Organisation for Animal Health** (WOAH) collaborating centre for veterinary medicinal products.

Fostering the development of innovative therapies

The ANMV supports the development of new therapeutic approaches. For example, it has proposed a specific assessment method for **herbal veterinary medicines or those based on essential oils**, to avoid risks for consumers of animal products. To give innovative companies a better idea of the authorisation procedures, the Agency has helped draw up guidelines in a number of cutting-edge fields such as **phage therapy**, **gene therapy** and **stem cells**.

Find out more about our missions
www.anses.fr

Contact us

↘ **French Agency for Veterinary Medicinal Products**
14 rue Claude Bourgelat – Parc d'activités de la Grande Marche – Javené
CS 70611 – F-35306 Fougères Cedex – France

ANSES Editions – April 2024 – Designed by BA–BA